Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of a placebo (an inactive substance with no therapeutic effect) and dutasteride, a small molecule drug used primarily to treat benign prostatic hyperplasia (BPH), or enlargement of the prostate gland, in adult males. Dutasteride is a 5-alpha reductase inhibitor that blocks both type I and type II isoforms of the enzyme responsible for converting testosterone to dihydrotestosterone (DHT). By reducing DHT levels, dutasteride decreases prostate size and improves urinary symptoms associated with BPH. Placebo serves as an inert comparator in clinical trials or studies evaluating the efficacy and safety of dutasteride[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo + dutasteride.